EU Regulators Back Daraxonrasib, the Pill That Nearly Doubled Survival in Advanced Pancreatic Cancer

Europe's medicines committee has recommended approval of daraxonrasib, an oral RAS-targeting drug for metastatic pancreatic cancer. In a 500-patient phase 3 trial, it extended median survival from 6.7 to 13.2 months compared with chemotherapy. Here is what the data show and what remains uncertain. On 26 August 2026, the FDA approved the oral drug daraxonrasib. Former US Senator Ben Sasse took it for stage 4 pancreatic cancer. It shrank his tumors and left him with a nasty bleeding skin rash.